(411) Disruption of the airway mucus barrier enhances nebulized RNA delivery to reverse pulmonary fibrosis

Nebulized RNA therapies are well suited for treating respiratory diseases, in particular pulmonary fibrosis (PF) (1); however, effective delivery remains challenging (2). Most studies have focused on the chemical surface modifications or physical structures of lipid nanoparticles (LNPs) to address nebulization challenges (3,4); however, these factors may not fully address the complexities of pulmonary RNA delivery, particularly within a diseased microenvironment.